Breaking News, Collaborations & Alliances

SK Bioscience to Support CEPI-Backed Development of Updated Zaire Ebolavirus Vaccine

The collaboration builds on MSD’s WHO-prequalified Zaire ebolavirus vaccine and focuses on updating the existing manufacturing process.

Author Image

By: Charlie Sternberg

Associate Editor

Left to right: John-Arne Røttingen, CEO, Wellcome; Priya Agrawal, VP Health Equity and Partnerships, MSD; Richard Hatchett, CEO, Coalition for Epidemic Preparedness Innovations (CEPI); Raman Rao, CEO, Hilleman Laboratories; Ikjung Kim, VP Head of Global Business Development, SK bioscience. Image courtesy of Eugene Zhylchuk.

SK Bioscience has joined a new international effort to advance an updated Zaire ebolavirus vaccine, following a funding agreement between the Coalition for Epidemic Preparedness Innovations (CEPI) and Merck & Co., known as MSD outside the U.S. and Canada. Under the terms of the agreement, CEPI will provide up to $30 million to MSD to continue development of the vaccine. MSD will distribute the funding among its partners, including SK Bioscience and Hilleman Laboratories, a joint venture b...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters